GRFS Grifols SA
Company Analysis
Latest News
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 24, 2026
Grifols SA is expected to report Q2 2026 revenue of $2.17 billion and an EPS of $0.27, while the stock currently trades around $8.25—well below the average...
🟢 Grifols rises 5.0% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 17, 2026
Grifols SA is expected to post Q2 2026 revenue of $2.01 billion and EPS of $0.27, with its current share price of $8.45 sitting significantly under the $12.10...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
For the second quarter of 2026, analysts anticipate Grifols to report a consensus revenue of $2.17 billion and an EPS of $0.27, while the current ADR price of...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 03, 2026
Grifols is expected to report Q2 2026 revenue of $2.06 billion and EPS of $0.27, with the stock currently trading at $9.45 against an average analyst price...
🔴 Grifols is trading 4.4% down today on potential profit-taking
Grifols is trading at $7.84 (down 4.4%) today as the stock faces downward pressure despite a lack of fresh, company-specific headlines. • The move follows a...
Grifols Profits Surge 29%, Driven by Strong Biopharma Demand
Grifols reported a 28.7% increase in net profit to €227 million for the first half of 2026. Revenues rose 2.6% at constant currency to €3.57 billion. The...
🟢 Grifols is trading 4.25% up today on continued idiosyncratic strength
Grifols is trading at $8.34 (+4.25%) in pre-market, extending its upward momentum following a 3.23% gain on July 28. • The move appears driven by...
🟢 Grifols is trading 4.1% up today, defying broader biotech sector weakness
Grifols is trading 4.1% up at $8.07 on above-average intraday strength despite a lack of clear company-specific catalysts. • The move stands out as the...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on July 27, 2026
Grifols is expected to report consensus revenue of $2.22 billion and an EPS of $0.28, with the stock currently trading at $7.61 compared to an average analyst...
🟢 Grifols is trading 4.2% up today amid broader risk-on sentiment
Grifols is trading at $7.58 (+4.20%) amid broader risk-on sentiment as the U.S. session continues. • The upward move appears to be taking place without a...
Grifols splits U.S. biopharma unit, seeking higher margins and independence
Grifols is reorganizing its global operations to grant subsidiaries greater financial and operational independence. The plan creates a standalone structure for...
🟢 GRFS is trading 5.9% up today on Phase 3 trial milestone
GRFS is trading at $7.50 (+5.9%) after-hours following news that the company dosed the first patient in its SWIFT-SC Phase 3 trial for a self-administered...
Grifols Doses First Patient in Phase 3 Trial, Targeting Self-Administered Treatment
Grifols dosed the first patient in its global SWIFT-SC Phase 3 clinical trial. This study evaluates a new subcutaneous formulation of Alpha1-Proteinase...
Grifols votes on 50% capital expansion, targeting US Nasdaq listing
Grifols SA convenes its Annual General Shareholders’ Meeting today, June 18, 2026. Shareholders will vote on key board resolutions during this second-call...